Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial
用户EO9nReo4Hj6s
1个月前
102
10
已完结
1. 系统已在2026-06-22 16:16:43对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/jco-25-02719
文献链接: https://ascopubs.org/doi/10.1200/JCO-25-02719
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Cheng Yang; Qi Jia; Chenglong Zhao; Xinghai Yang; Haifeng Wei; Tielong Liu; Jian Jiao; Zhipeng Wu; Jian Zhao; Wei Xu; Zhenhua Zhou; Wei Wan; Weiwei Zou; Zhi Zhu; Xiaomei Ma; Qi Chen; Wei Guo; Dongqing Zhu; Tao Tan; Yan Lou; Juelan Ye; Jingyu Xing; Hao Zhang; Zijie Yuan; Jianru Xiao
